Search company, investor...

Tacere Therapeutics

Founded Year



Seed VC | Alive

About Tacere Therapeutics

Tacere Therapeutics, Inc. specializes in the development of both traditional and therapeutics for the treatment of Hepatitis C (HCV). Combining expertise in small molecules, gene medicine, and RNA interference (RNAi), Tacere possesses skill in the screening and identification of both pharmaceutical and biological agents for the treatment of this major unmet medical need.

Headquarters Location

5941 Optical Court

San Jose, California, 95138,

United States


Missing: Tacere Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Tacere Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Tacere Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tacere Therapeutics is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Tacere Therapeutics News

Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.’s Scientific Advisor Board

Sep 17, 2013

Senior Vice President of Research and Development at Tacere Therapeutics (a Subsidiary of Benitec Biopharma) to Help Guide Regen's Cancer Immunotherapy Program SAN DIEGO, CA--(Marketwired - Sep 17, 2013) - Bio-Matrix Scientific Group Inc. ( OTCQB : BMSN ) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"), a subsidiary of Bio-Matrix Scientific Group Inc. "Dr. Suhy, a pioneer of the RNAi industry, was already developing therapeutic candidates in this field in 2003 before the concept of RNAi was accepted in the scientific community," said David Koos, Chairman & CEO of Regen. "We are excited to apply Dr. Suhy's experience in the development of our RNAi based cancer therapeutic. " Regen's Chief Scientific Officer, Dr. Thomas Ichim, noted, "Dr. David Suhy, senior vice president of research and development at Tacere Therapeutics (a subsidiary of Benitec Biopharma), leads all Tacere's clinical development programs. He was one of the inventors of TT-034, a novel therapeutic product containing three separate RNAi elements targeted against the Hepatitis C virus, and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies. "  A spokesperson for the Company provided further insight on RNAi, stating this is a process by which genes may be selectively blocked using a natural mechanism the body normally uses to protect against viruses. The Nobel Prize in Medicine was awarded to Fire and Mello in 2006 for making this discovery. Benitec has been granted international patents on RNAi which have been licensed to Regen for one specific gene, indolamine 2,3 deoxygenase (IDO), which is associated with cancer's ability to suppress the immune system. Regen Chief Scientific Officer Dr. Thomas Ichim together with Professor Weiping Min at the University of Western Ontario have successfully treated breast cancer (1) and melanoma (2) in animals using this approach. "With Regen's background in the field of tumor immunology, their licensed intellectual property from Benitec Biopharma, and clinical expertise, I look forward to assisting the Company in developing their protocols with the end goal being taking this safe and nontoxic cancer therapy to patients," said Dr. Suhy. References 1. Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77. 2. Zheng et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46. About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. Contact Information Bio-Matrix Scientific Group, Inc. and Regen BioPharma Inc.

Tacere Therapeutics Frequently Asked Questions (FAQ)

  • When was Tacere Therapeutics founded?

    Tacere Therapeutics was founded in 2006.

  • Where is Tacere Therapeutics's headquarters?

    Tacere Therapeutics's headquarters is located at 5941 Optical Court, San Jose.

  • What is Tacere Therapeutics's latest funding round?

    Tacere Therapeutics's latest funding round is Seed VC.

  • Who are the investors of Tacere Therapeutics?

    Investors of Tacere Therapeutics include Hokkaido Venture Capital and Oncolys BioPharma.

  • Who are Tacere Therapeutics's competitors?

    Competitors of Tacere Therapeutics include Aquinox Pharmaceuticals, Viridian Therapeutics, Intarcia Therapeutics, Eiger BioPharmaceuticals, Nora Therapeutics and 12 more.

Compare Tacere Therapeutics to Competitors

Icagen Logo

Icagen partners with pharmaceutical and biotechnology companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. The Icagen team has experience advancing molecules from drug discovery to clinical development across multiple therapeutic areas and ion channel classes. Icagen's tool box comprises a range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, enables high throughput assessment of ion channels and transporters, including challenging systems with high therapeutic interest.


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.


MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

Altheus Therapeutics

Altheus Therapeutics is developing Zoenasa Oral Controlled Release and Rectal Gel formulations as front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus an antioxidant to reduce bowel injury associated with IBD. Zoenasa is formulated as a rectal gel enema to improve efficacy in patients suffering from left-sided (distal) ulcerative colitis; and as oral formulations with an extended- and delayed-release profile for patients with proximal or extensive colitis.

Progression Therapeutics

Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.